Aprecia, the leader in 3DP pharmaceutical manufacturing, developed ZipDose® Technology, the first and only 3DP technology platform used in an FDA approved product. Aprecia uses its ZipDose® Technology to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer. Without compression during the 3DP manufacturing process, engineered and coated particles such as taste masking and modified release are possible on large dose products (over a 1000mg). Aprecia directly owns a patent estate for novel 3DP machines and pharmaceutical 3DP applications. It licenses its exclusive technology platform to pharmaceutical partners as a means to extend product lines, improve patient reach and experience, and address FDA requirements as a pediatric delivery form. Aprecia is committed to enhancing the patient experience through novel approaches to drug delivery and enabling pharmaceutical scientists the freedom to develop products not available with traditional equipment and technology. For more information, visit www.aprecia.com.